XINTELA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.255 SEK | -6.25% |
|
-5.90% | -5.90% |
| 02-28 | Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| 02-20 | Xintela Names New Chief Scientific Officer | MT |
| Sales 2022 | - | Sales 2023 | 78K 7.22K 574K | Capitalization | 148M 13.69M 1.09B |
|---|---|---|---|---|---|
| Net income 2022 | -66M -6.11M -486M | Net income 2023 | -54M -5M -398M | EV / Sales 2022 | - |
| Net cash position 2022 | 8.34M 772K 61.43M | Net cash position 2023 | 7.81M 723K 57.5M | EV / Sales 2023 | 1,797 x |
| P/E ratio 2022 |
-1.33
x | P/E ratio 2023 |
-2.1
x | Employees | 21 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 31.28% |
More Fundamentals
* Assessed data
More news
| 1 day | -6.25% | ||
| 1 week | -5.90% | ||
| Current month | -6.93% | ||
| 1 month | -5.90% | ||
| 3 months | +0.79% | ||
| 6 months | +1.19% | ||
| Current year | -5.90% |
1 week
0.26
0.29
1 month
0.260.33
Current year
0.210.35
1 year
0.200.35
3 years
0.203.25
5 years
0.206.30
10 years
0.208.92
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 67 | 31/12/08 | |
Gunnar Telhammar
DFI | Director of Finance/CFO | 63 | 31/12/12 |
Thomas Areschoug
PRN | Corporate Officer/Principal | 52 | 28/02/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lars Olof Hedbys
BRD | Director/Board Member | 67 | 31/12/20 |
| Chairman | 67 | 31/12/10 | |
| Director/Board Member | 64 | 31/12/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/05/24 | 0.255 | -6.25% | 87 795 |
| 03/05/24 | 0.272 | -4.56% | 55,246 |
| 02/05/24 | 0.285 | +4.01% | 113,931 |
| 30/04/24 | 0.274 | +1.11% | 155,311 |
| 29/04/24 | 0.271 | -3.56% | 211,514 |
Delayed Quote Nasdaq Stockholm, May 06, 2024 at 04:23 pm
More quotes
Xintela AB (Xintela) is a Sweden-based biomedical company engaged in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumors. In the field of regenerative medicine, the Company focuses on cartilage damage and osteoarthritis, and in the field of brain tumors, its focuses on the development of a treatment for glioblastoma, an aggressive tumor. The Company has developed therapeutic antibodies, which bind to cancer cells. It has also developed XINMARK, a marker technology which consists of specific proteins, which work as recognition flags on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells.
Calendar
07/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -5.90% | 14.28M | |
| +21.95% | 47.9B | |
| +46.56% | 41.42B | |
| -2.58% | 40.7B | |
| -6.20% | 28.92B | |
| +10.81% | 25.55B | |
| -21.66% | 19.27B | |
| -1.50% | 12.15B | |
| +30.61% | 12.14B | |
| -0.78% | 11.99B |
- Stock Market
- Equities
- XINT Stock
